Blood test may replace brain scans for Alzheimer's drug monitoring
NCT ID NCT07153848
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 400 people with early Alzheimer's who are taking the drug lecanemab. Researchers want to see if simple blood tests can detect whether the drug is reducing amyloid plaques in the brain, which is currently measured with expensive PET scans. The goal is to find a cheaper, easier way to monitor treatment effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lecanemab
What this could lead to
If successful, this study could show that simple blood tests can track whether lecanemab is clearing amyloid plaques from the brain, potentially reducing the need for expensive PET scans.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The results may not apply to all Alzheimer's patients, and blood biomarkers may not reliably match brain changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••